-

Medable Announces its Continued Commitment to Global Privacy and Data Protection Through Earned CIPP/E Certification

PALO ALTO, Calif.--(BUSINESS WIRE)--Medable Inc., the end-to-end platform for digitally enabled and data-driven clinical trials, today announced that Andrea Sanchez, Vice President Legal & SaMD secured CIPP/E Certification.

A member of the State Bar of Texas and J.D. from Baylor Law School, Andrea earned the ANSI-accredited Certified Information Privacy Professional/Europe (CIPP/E) credential through the International Association of Privacy Professionals (IAPP). “As an attorney and privacy professional, Andrea already brings significant privacy and data protection capabilities to Medable. Recognition of Andrea’s knowledge and expertise via the CIPP/E credential further demonstrates Medable’s own commitment to privacy and data protection globally, and in particular, data protection in the EU.,” said Perry Robinson, Chief Legal & Compliance Officer at Medable.

Medable currently serves customers across the globe and continues to expand its service offerings in the clinical trial space and in its leadership position in the digital trial space.

In addition to the CIPP/E credential, Andrea holds the CIPP/US credential. The CIPP is the global standard in privacy certification. Developed and launched by the IAPP with leading subject matter experts, the CIPP is the world’s first broad-based global privacy and data protection credentialing program.

The CIPP/US demonstrates a strong foundation in U.S. private-sector privacy laws and regulations and an understanding of the legal requirements for the responsible transfer of sensitive personal data to/from the U.S., the EU, and other jurisdictions.

The CIPP/E is the first professional credential specific to European data protection professionals that is part of a comprehensive, principles-based framework and knowledge base in information privacy. The CIPP/E encompasses pan-European and national data protection laws, the European model for privacy enforcement, key privacy terminology and practical concepts concerning the protection of personal data and trans-border data flows. Andrea joins the ranks of professionals worldwide who currently hold one or more IAPP certifications.

About Medable

Medable is a privately held, venture-backed company headquartered in Palo Alto, California. Medable is on a mission to get effective therapies to patients faster by dramatically reducing the time from therapeutic development to market realization with digital data capture and real-time analytics that remove the complexities of clinical research to dramatically reduce trial timelines. Medable is pioneering a new category of life science technologies that replace the stagnant and siloed data of traditional ePRO, eCOA, EDC, and eSource with an intelligent and unified end-to-end (E2E) platform for clinical trial execution. Medable’s end-to-end digital trial platform allows patients, healthcare providers, clinical research organizations and pharmaceutical sponsors to work together as a connected and empowered team in clinical trials and research.

Contacts

Investors
Medable
investors@medable.com

Media
Letitia Rodley, VP Marketing
Media@Medable.com

Medable Inc.

Details
Headquarters: Palo Alto, California
CEO: Michelle Longmire
Employees: 350
Organization: PRI

Release Summary
Medable announces its continued commitment to global privacy and data protection through earned CIPP/E certification
Release Versions

Contacts

Investors
Medable
investors@medable.com

Media
Letitia Rodley, VP Marketing
Media@Medable.com

Social Media Profiles
More News From Medable Inc.

MRCT Center and Medable Launch New Resources for Investigator Oversight in Decentralized Clinical Trials

PALO ALTO, Calif.--(BUSINESS WIRE)--Medable Inc., a leading provider of agentic clinical development technology, and the Multi-Regional Clinical Trials Center of Brigham and Women’s Hospital and Harvard (MRCT Center) today announced new resources for sponsors and investigators. The tools will be available beginning September 23, 2026. The resources and practical tools help sponsors and investigators determine which trial activities can appropriately take place closer to participants and establi...

Medable and ICON Exceed Patient eConsent Adoption Goals for Women’s Health Study on Menopause

PALO ALTO, Calif.--(BUSINESS WIRE)--Medable Inc., the leading technology platform for agentic AI clinical development, today announced the impact of its Total Consent solution in a U.S women’s health study on menopause managed by ICON plc. Beating expectations, more than 85% of trial participants, or 1,044 out of 1,222, consented using Medable’s enhanced eConsent technology. And, 18 sites achieved 100% eConsent adoption among participants, while the top-enrolling site achieved 91% adoption. With...

New Tufts CSDD Analysis Finds AI Agents Can Deliver Up to $21 Million in Net Financial Value Per Drug Development Program and Up to 82x ROI

PALO ALTO, Calif.--(BUSINESS WIRE)--Medable Inc., the leading technology platform for agentic clinical development, today announced a new Tufts Center for the Study of Drug Development (CSDD) analysis showing that an AI clinical monitoring agent can deliver net financial gains as high as $21 million per drug development program and 82 times the return on investment. The findings are based on benchmarked oncology program and clinical trial data from Tufts CSDD and contract value and experience d...
Back to Newsroom